

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC (Last) (First) (Middle) 929 NORTH FRONT STREET (Street) WILMINGTON NC 28401 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol Liquidia Technologies Inc [LQDA]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 07/30/2018	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)			4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price				
Common stock	07/30/2018		C		442,819	A	(1)	442,819	D(2)(3)		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					
Series C Preferred Stock	(1)	07/30/2018		C		3,420,516		(1)	(1)	Common Stock	442,819	\$0	0	D(2)(3)

1. Name and Address of Reporting Person*
PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC
 (Last) (First) (Middle)
929 NORTH FRONT STREET
 (Street)
WILMINGTON NC 28401
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
Wildcat Acquisition Holdings (UK) Ltd
 (Last) (First) (Middle)
929 NORTH FRONT STREET
 (Street)
WILMINGTON NC 28401
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
Jaguar Holding Co II
 (Last) (First) (Middle)
929 NORTH FRONT STREET
 (Street)

WILMINGTON	NC	28401
(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
Jaguar Holding Co I, LLC		
(Last)	(First)	(Middle)
929 NORTH FRONT STREET		
(Street)		
WILMINGTON	NC	28401
(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
Eagle Holding Co II, LLC		
(Last)	(First)	(Middle)
929 NORTH FRONT STREET		
(Street)		
WILMINGTON	NC	28401
(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
Eagle Holding Co I		
(Last)	(First)	(Middle)
929 NORTH FRONT STREET		
(Street)		
WILMINGTON	NC	28401
(City)	(State)	(Zip)

Explanation of Responses:

1. The Series C Preferred Stock had no expiration date and automatically converted into the Issuer's common stock on approximately a 0.1295-for-1 basis immediately prior to the closing of the Issuer's initial public offering.
2. These securities are held of record by Pharmaceutical Product Development, LLC ("Pharma LLC"). Wildcat Acquisition Holdings (UK) Limited ("Wildcat") is the sole member of Pharma LLC; Jaguar Holding Company II ("Jaguar II") is the sole shareholder of Wildcat; Jaguar Holding Company I, LLC ("Jaguar I") is the sole shareholder of Jaguar II; Eagle Holding Company II, LLC ("Eagle II") is the sole member of Jaguar I; and Eagle Holding Company I is the sole member of Eagle II. By virtue of such relationships, each of the reporting persons may be deemed to have beneficial ownership over such securities.
3. This report on Form 4 is jointly filed by the reporting persons. Each of the reporting persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes.

[PHARMACEUTICAL
PRODUCT DEVELOPMENT,
LLC By: /s/ William J.
Sharbaugh, Name: William J. Sharbaugh, Title: Chief
Operating Officer](#) 08/01/2018

[WILDCAT ACQUISITION
HOLDINGS \(UK\) LIMITED
By: /s/ William J. Sharbaugh, Name: William J. Sharbaugh
Title: Director](#) 08/01/2018

[JAGUAR HOLDING
COMPANY II By: /s/ William
J. Sharbaugh, Name: William J. Sharbaugh, Title: Chief
Operating Officer](#) 08/01/2018

[JAGUAR HOLDING
COMPANY I, LLC By: /s/
William J. Sharbaugh, Name: William J. Sharbaugh, Title:
Chief Operating Officer](#) 08/01/2018

[EAGLE HOLDING
COMPANY II, LLC By: /s/
William J. Sharbaugh, Name: William J. Sharbaugh, Title:
Chief Operating Officer](#) 08/01/2018

[EAGLE HOLDING
COMPANY I By: /s/ William J.
Sharbaugh, Name: William J.](#) 08/01/2018

Sharbaugh Title: Chief
Operating Officer

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.